18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

This phase I/II trial studies fluorine 18 2-fluoropropionyl-labeled pegylated dimeric arginine-glycine-aspartic acid (RGD) peptide (18F FPPRGD2) positron emission tomography (PET)/computed tomography (CT) in predicting early response in patients with cancer receiving anti-angiogenesis therapy. Diagnostic procedures, such as 18F FPPRGD2 PET/CT, may be a less invasive method of finding cancer early and determining response to treatment


Primary Contact:
Jonathan Euodia
(650) 723-7419